Overview

A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin

Status:
Completed

Trial end date:
2015-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the effect of canagliflozin (JNJ-28431754) compared to placebo in the treatment of participants with Type 2 Diabetes Mellitus (T2DM), who have inadequate glycemic control on maximally or near-maximally effective doses of metformin and sitagliptin.

Phase:

Phase 4

Details

Lead Sponsor:

Janssen Research & Development, LLC

Treatments:

Canagliflozin
Metformin
Sitagliptin Phosphate